Clinical trial NCT02793349: The ABSORB Bioresorbable Scaffold Below the Knee (BTK) Study
Official title: ABSORB BTK Study: A Prospective, Multi-center, Controlled Clinical Evaluation of the Use of a Bioresorbable Drug Eluting Stent (Absorb, Abbott Vascular) in the Arterial Vasculature Below the Knee
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Ischemia
Peripheral Arterial Disease (PTA
Arterial Occlusive Diseases
Keywords: angioplasty
stents
polymers
absorbable implants
Lead sponsor: The University of New South Wales
Sponsor class: OTHER
First posted: 2016-06-08
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: ABSORB BTK Study: A prospective, multicenter, controlled clinical evaluation of the use of a bioresorbable drug eluting stent in the arterial vasculature below the knee

Detailed description: The aim of this study is to evaluate the performance of a bioresorbable vascular scaffold (BVS) coated with the drug Everolimus. This will be used to treat short length blockages of up to 55mm (5.5cm) in arteries below the knee.

This will be performed to treat patients who have severe leg pain or have developed skin ulcers or gangrene which are not healing due to insufficent blood supply. The ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold works on similar principles of drug eluting stents which have been used for a considerable time in treating blocked arteries. However this product consists of a scaffold coated with a drug so rather than leaving a metallic stent in the blood vessel, this product primarily delivers the drug, gives mechanical support to the blood vessel and once it is no longer needed the scaffold absorbs into the body leaving no permanent metallic implant.

This same device has been used safely and effectively in the arteries which supply the heart both in clinical trials and current practice and has also been evaluated in the leg arteries in a single-centre pilot study. This study aims to evaluate it's use in a larger number of patients in multiple centres and compare that to a historical control group of metal drug eluting stents. The study will evaluate both ultrasound and angiographic derived patency in those arteries out to a 36 month follow-up time point. This data will be collected in patients who fulfill the inclusion criteria and who are then treated and followed over time.

Eligibility criteria: Inclusion Criteria:

* Stenotic (\> 50%) or occlusive atherosclerotic disease of the distal popliteal or infrapopliteal arteries
* A maximum of two focal target lesions in one or more distal popliteal or infrapopliteal vessels
* Length of lesion is maximally 55 mm, allowing maximally 2 stents to be implanted
* Reference vessel diameter should be 2.5 mm-4 mm
* Symptomatic critical limb ischemia (Rutherford 3, 4, 5)
* Subject is able to take at least one type of thienopyridine (e.g. clopidogrel) and acetylsalicylic acid
* The patient must be \> 18 years of age
* Life-expectancy of more than 12 months
* The patient has no child bearing potential or negative serum pregnancy test within 7 days of the index procedure
* The patient must be willing and able to return to the appropriate follow-up times for the duration of the study
* The patient must provide written patient informed consent that is approved by the ethics committee

Exclusion Criteria:

* Patient refusing treatment
* The reference segment diameter is not suitable for available stent design.
* Unsuccessfully treated (\>30% residual stenosis) proximal inflow limiting arterial stenosis
* Untreatable lesion located at the distal outflow arteries
* More than two infrapopliteal lesions in the same limb
* Previously implanted stent(s) or PTA at the same lesion site
* Lesion location requiring kissing stent procedure
* Lesion lies within or adjacent to an aneurysm
* Inflow-limiting arterial lesions left untreated
* The patient has a known allergy to heparin, Aspirin or other anticoagulant/anti-platelet therapies or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies.
* The patient takes Phenprocoumon (Marcumar).
* The patient has a history of prior life-threatening contrast media reaction.
* The patient is currently enrolled in another investigational device or drug trial.
* The patient is currently breast-feeding, pregnant or intends to become pregnant.
* The patient is mentally ill or retarded.
* Subject has received a heart transplant or any other organ transplant or is on a waiting list for any organ transplant
* Subject is receiving or scheduled to receive anticancer therapy for malignancy within 30 days prior to or after the procedure
* Subject is receiving immunosuppression therapy, or has known serious immunosuppressive disease (e.g., human immunodeficiency virus), or has severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., systemic lupus erythematosus, etc.) The patient should also not receive inhibitors of CYP3A (such as Itraconazole, and Erythromycin), or inducers of CYP3A (Cytochrome P450 3A4) (such as Rifampin) within 90 days following the procedure.
* Subject is receiving or is scheduled to receive chronic anticoagulation therapy (e.g., heparin, coumadin)
* Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation therapy) as part of the index procedure

Primary outcomes:
measure: Angiographic patency
timeFrame: 12 months
Secondary outcomes:
measure: Technical success
timeFrame: Procedure
measure: Haemodynamic primary, assisted primary and secondary patency
timeFrame: 1 month
measure: Haemodynamic primary, assisted primary and secondary patency
timeFrame: 6 months
measure: Haemodynamic primary, assisted primary and secondary patency
timeFrame: 12 months
measure: Haemodynamic primary, assisted primary and secondary patency
timeFrame: 24 months
measure: Haemodynamic primary, assisted primary and secondary patency
timeFrame: 36 months
measure: Limb salvage rate (LSR)
timeFrame: 12 months
measure: Target lesion revascularization (TLR)
timeFrame: 12 months
measure: Rutherford Category
timeFrame: 12 months
measure: Adverse clinical events
timeFrame: 12 months
Other outcomes:
Locations:
city: Sydney
country: Australia
facility: Prince of Wales Hospital
state: New South Wales
city: Melbourne
country: Australia
facility: Epworth Hospital
state: Victoria
city: Delft
country: Netherlands
facility: Reinier de Graf Hospital
city: Auckland
country: New Zealand
facility: Auckland City Hospital
Study officials:
affiliation: Prince of Wales Hospital
name: Ramon L Varcoe, MS,FRACS,PhD
role: PRINCIPAL_INVESTIGATOR
References: